Artificial intelligence (AI) surely stands at the forefront of one of the most transformative periods in the pharmaceutical industry. Its rapid drug discovery capabilities and potential for personalized patient care mark AI as a revolutionary influence in reshaping the pharmaceutical industry. Central to this transformation is natural language processing (NLP).
Tag Archive for: Drug development
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the critical organ in a mid-stage trial.
Yesterday the agency published a revised draft guidance document, aimed at helping sponsors and pharmaceutical companies to develop therapies for Alzheimer’s disease, particularly in its early stages before the onset of overt dementia.
Eli Lilly announced late-breaking results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
The CEO of the world’s biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like malaria and dengue by repurposing facilities used to make COVID-19 immunizations.
The Danish drugmaker hopes to develop amycretin in its oral and injectable form simultaneously.
The early-stage oncology startup filed for an initial public offering on Wednesday, seeking funds to help develop its novel cancer therapies targeting extrachromosomal DNA.
Novo Nordisk said early trial data for its highly anticipated experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment, sending its shares to new record highs.
The company’s planned investment includes 450 million pounds to research, develop and manufacture vaccines at its manufacturing site in Speke, Liverpool, and another 200 million pounds to expand its existing presence in Cambridge, where its global headquarters are located.
At yesterday’s Oncology Innovation Day, Pfizer laid out its business strategy which includes building up its biologics business, specifically antibody-drug conjugates and bispecific antibodies.